passive immunization

Summary

Alias: passive immunotherapy, immunoglobulin therapy
Summary: Transfer of immunity from immunized to non-immune host by administration of serum antibodies, or transplantation of lymphocytes (ADOPTIVE TRANSFER).

Webpages

  1. untitled document
    www.nih.go.jp/JJID/LEC-90.html
  2. neurotoxins
    microvet.arizona.edu/Courses/MIC454/Secure/cytolyticNotes.ht ...
  3. mchsecond and third trimester of pregnancy
    faculty.washington.edu/alexbert/MEDEX/Winter/MCHSecondThirdT ...
  4. production and characterization of therapeutic anti-idiotypic antibodies for control of diarrhea caused by escherichia coli k88
    www.omaf.gov.on.ca/english/livestock/animalcare/amr/facts/ja ...
  5. the wistar institute :: dorothee herlyn, d.v.m., d.sc
    www.wistar.org/research_facilities/dherlyn/research.htm
  6. st. boniface general hospital research centre - dr. michelle alfa
    www.sbrc.ca/content/blogcategory/81/126/index.html
  7. st. boniface general hospital research centre - microbiology and infectious diseases
    www.sbrc.ca/content/blogcategory/81/125/index.html
  8. online health topics
    www.uhs.berkeley.edu/home/healthtopics/chickenpox.shtml
  9. the forsyth institute: scientists & research - martin a. taubman
    www.forsyth.org/research/scientists/profiles/mtaubman.html
  10. wvu :: school of medicine :: obstetrics and gynecology
    www.hsc.wvu.edu/som/obgyn/research.asp

Research Grants

  1. Pacific-Southwest Ctr for Biodefense & Emerg Infect Dis*
    Alan G Barbour; Fiscal Year: 2008
  2. Pacific-Southwest Ctr for Biodefense & Emerg Infect Dis*
    Alan G Barbour; Fiscal Year: 2007
  3. Humanized Antibodies Derived from Chimpanzee Fabs that N
    CHING JUH LAI; Fiscal Year: 2006
  4. Hepatitis C: Studies of Immunity and Pathogenesis
    Charles M Rice; Fiscal Year: 2008
  5. Hepatitis C: Studies of Immunity and Pathogenesis
    Charles M Rice; Fiscal Year: 2005
  6. Hepatitis C: Studies of Immunity and Pathogenesis
    Charles M Rice; Fiscal Year: 2007
  7. Immunomodulation by exogenous streptococcal antibody
    L Jeannine Brady; Fiscal Year: 2008
  8. Immunomodulation by exogenous streptococcal antibody
    L Jeannine Brady; Fiscal Year: 2007
  9. CLINICAL TRIALS OF CD4 IGG2 AND HUMAB COMBINATIONS
    Paul J Maddon; Fiscal Year: 2002
  10. Protective Human Monoclonal Antibodies to HIV-1
    SUSAN B ZOLLA-PAZNER; Fiscal Year: 2008

Publications

  1. Effect of sleep deprivation on serum influenza-specific IgG
    K B Renegar
    Department of Physiology and Biophysics, University of Tennessee, Memphis, USA
    Sleep 21:19-24
  2. Pneumococcal surface protein A is expressed in vivo, and antibodies to PspA are effective for therapy in a murine model of pneumococcal sepsis
    E Swiatlo
    Department of Medicine, University of Alabama at Birmingham, USA
    Infect Immun 71:7149-53
  3. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract
    Kathryn B Renegar
    Division of Infectious Diseases, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    J Immunol 173:1978-86
  4. Protection of mice against Human respiratory syncytial virus by wild-type and aglycosyl mouse-human chimaeric IgG antibodies to subgroup-conserved epitopes on the G glycoprotein
    C Mekseepralard
    The Schools of Clinical Medical Sciences and Cell and Molecular Biosciences, The University of Newcastle upon Tyne, UK
    J Gen Virol 87:1267-73
  5. Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants
    Jianhua Sui
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, 44 Binney St, JFB 824, Boston, MA 02115, USA
    J Virol 79:5900-6
  6. Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection
    Jean Mukherjee
    Tufts University School of Veterinary Medicine, North Grafton, Massachusetts 01536, USA
    Infect Immun 70:612-9
  7. Protection of mice against experimental Japanese encephalitis virus infections by neutralizing anti-glycoprotein E monoclonal antibodies
    A K Gupta
    National Institute of Virology, Indian Council of Medical Research, 20 A, Dr Ambedkar Road, P O B No 11, Pune 411001, India
    Acta Virol 47:141-5
  8. Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice
    Thomas C Greenough
    Department of Pediatrics, Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts 02130, USA
    J Infect Dis 191:507-14
  9. Cellular localization and antigenic characterization of crimean-congo hemorrhagic fever virus glycoproteins
    Andrea Bertolotti-Ciarlet
    Department of Microbiology, University of Pennsylvania, 225 Johnson Pavilion, 3610 Hamilton Walk, Philadelphia, PA 19104, USA
    J Virol 79:6152-61
  10. Efficient mother-to-child transfer of antiretroviral immunity in the context of preclinical monoclonal antibody-based immunotherapy
    Laurent Gros
    Institut de Génétique Moléculaire de Montpellier, UMR 5535 IFR 122, CNRS, 1919 Route de Mende, 34293 Montpellier Cedex 5, France
    J Virol 80:10191-200

Scientific Experts

Detail Information

Webpages49 found, 30 most recent shown here

  1. untitled document
    www.nih.go.jp/JJID/LEC-90.html
  2. neurotoxins
    microvet.arizona.edu/Courses/MIC454/Secure/cytolyticNotes.ht ...
  3. mchsecond and third trimester of pregnancy
    faculty.washington.edu/alexbert/MEDEX/Winter/MCHSecondThirdT ...
  4. production and characterization of therapeutic anti-idiotypic antibodies for control of diarrhea caused by escherichia coli k88
    www.omaf.gov.on.ca/english/livestock/animalcare/amr/facts/ja ...
  5. the wistar institute :: dorothee herlyn, d.v.m., d.sc
    www.wistar.org/research_facilities/dherlyn/research.htm
  6. st. boniface general hospital research centre - dr. michelle alfa
    www.sbrc.ca/content/blogcategory/81/126/index.html
  7. st. boniface general hospital research centre - microbiology and infectious diseases
    www.sbrc.ca/content/blogcategory/81/125/index.html
  8. online health topics
    www.uhs.berkeley.edu/home/healthtopics/chickenpox.shtml
  9. the forsyth institute: scientists & research - martin a. taubman
    www.forsyth.org/research/scientists/profiles/mtaubman.html
  10. wvu :: school of medicine :: obstetrics and gynecology
    www.hsc.wvu.edu/som/obgyn/research.asp
  11. channing laboratory - johannes huebner, md
    www.channing.harvard.edu/huebner.htm
  12. the forsyth institute: scientists & research - daniel j. smith
    www.forsyth.org/research/scientists/profiles/dsmith.html
  13. jhu - cone lab - research
    biophysics.jhu.edu/cone/research.html
  14. tetanus immune globulin (human
    www.umm.edu/altmed/drugs/tetanus-immune-122800.htm
  15. cornell university :: program in virology :: faculty
    virology.cornell.edu/faculty.htm
  16. prevention of hepatitis a through active or passive immunization: recommendations of the advisory committee on immunization practices (acip
    www.cdc.gov/mmwR/preview/mmwrhtml/rr5507a1.htm
  17. adult health advisor 2009.1: guillain-barré syndrome
    www.fairview.org/healthlibrary/content/aha_guillain_crs.htm
  18. senior health advisor 2009.1: guillain-barré syndrome
    www.fairview.org/healthlibrary/content/sha_guillain_crs.htm
  19. greenville hospital system
    www.ghs.org/HealthContent.aspx?id=72048
  20. immune response - overview
    www.umm.edu/ency/article/000821.htm
  21. common variable immunodeficiency (cvid) - allergy, asthma, and immunology - health library - children's hospital of the king's daughters
    www.chkd.com/Allergy/cvid.asp
  22. common variable immunodeficiency (cvid
    www.childrens.com/HealthLibrary/HealthLibContent.cfm?pageid= ...
  23. crsn: xxiiie symposium, résumé - abstract
    www.crsn.umontreal.ca/XXIIIs/abs-conf/david_s.html
  24. our physicians - health information
    www.memorialhealth.com/healthinfo/content.aspx?pageid=P01680
  25. epstein-barr virus infections clinical resources
    guam-dl.slis.ua.edu/clinical/infectious/byorganism/viral/eps ...
  26. bronchitis clinical resources
    unthsc-dl.slis.ua.edu/clinical/pulmonology/bronchialdiseases ...
  27. immunization, passive
    buchta.lib.bioinfo.pl/meid:3927
  28. institute for neurodegenerative disorders
    www.indd.org/NewHavenRegisterArt..html
  29. g“c‰hl
    www.jichi.ac.jp/idoubutsu/Yoshida publication.html

Research Grants62

  1. Pacific-Southwest Ctr for Biodefense & Emerg Infect Dis*
    Alan G Barbour; Fiscal Year: 2008
    ..Project 5 will use murine and rabbit models of pulmonary anthrax to evaluate active and passive immunization that targets the capsule and the role of strain diversity in capsule-targeted immunity...
  2. Pacific-Southwest Ctr for Biodefense & Emerg Infect Dis*
    Alan G Barbour; Fiscal Year: 2007
    ..Project 5 will use murine and rabbit models of pulmonary anthrax to evaluate active and passive immunization that targets the capsule and the role of strain diversity in capsule-targeted immunity...
  3. Humanized Antibodies Derived from Chimpanzee Fabs that N
    CHING JUH LAI; Fiscal Year: 2006
    ..b>Passive immunization by transfer of monoclonal antibody represents an attractive alternative to a vaccine against dengue or ..
  4. Hepatitis C: Studies of Immunity and Pathogenesis
    Charles M Rice; Fiscal Year: 2008
    ..of conserved neutralization determinants that can be integrated into strategies for vaccination or passive immunotherapy. In addition, this panel of recombinant HCVcc expressing convenient reporters will facilitate screening ..
  5. Hepatitis C: Studies of Immunity and Pathogenesis
    Charles M Rice; Fiscal Year: 2005
    ..of conserved neutralization determinants that can be integrated into strategies for vaccination or passive immunotherapy. In addition, this panel of recombinant HCVcc expressing convenient reporters will facilitate screening ..
  6. Hepatitis C: Studies of Immunity and Pathogenesis
    Charles M Rice; Fiscal Year: 2007
    ..of conserved neutralization determinants that can be integrated into strategies for vaccination or passive immunotherapy. In addition, this panel of recombinant HCVcc expressing convenient reporters will facilitate screening ..
  7. Immunomodulation by exogenous streptococcal antibody
    L Jeannine Brady; Fiscal Year: 2008
    ..understand the consequences and underlying molecular mechanisms of immunomodulation and would be of general interest for any active or passive immunization approach. Public Health Relevance: This Public Health Relevance is not available.
  8. Immunomodulation by exogenous streptococcal antibody
    L Jeannine Brady; Fiscal Year: 2007
    ..P1 antigen and MAbs against it represent an excellent model system to understand the consequences and underlying molecular mechanisms of immunomodulation and would be of general interest for any active or passive immunization approach.
  9. CLINICAL TRIALS OF CD4 IGG2 AND HUMAB COMBINATIONS
    Paul J Maddon; Fiscal Year: 2002
    ..and CD4-IgG2 exhibit significant neutralization activity as single agents, the development of an effective passive immunotherapy may require the use of mixtures of two or more of these agents...
  10. Protective Human Monoclonal Antibodies to HIV-1
    SUSAN B ZOLLA-PAZNER; Fiscal Year: 2008
    ..virus replication, and will inform the design of reagents for use in active immunization (vaccines), passive immunization, and immunotherapy...
  11. Immunization to Block the Effects of Nicotine
    Paul R Pentel; Fiscal Year: 2008
    ..b>Passive immunization with nicotine-specific monoclonal antibodies, an alternative to vaccination, is highly effective in animals ..
  12. Mucosal Abeta Vaccination: Modulating the Immune Response
    Cynthia A Lemere; Fiscal Year: 2008
    ..A new clinical trial is underway to test the safety of passive immunization by monthly intravenous injections of humanized Abeta monoclonal antibodies...
  13. Mucosal Abeta Vaccination: Modulating the Immune Response
    Cynthia A Lemere; Fiscal Year: 2007
    ..A new clinical trial is underway to test the safety of passive immunization by monthly intravenous injections of humanized Abeta monoclonal antibodies...
  14. Neutralizing human mAbs: study in HIV-exposed babies
    Hoosen Coovadia; Fiscal Year: 2004
    ..Our long-range goal is to prevent HIV transmission through breastfeeding by passive immunization with combinations of human neutralizing monoclonal antibodies (nmAbs)...
  15. Recombinant Antibodies for Neonatal HSV Prophylaxis
    Pietro P Sanna; Fiscal Year: 2005
    ..Therefore, passive immunization with selected human monoclonal antibodies could be beneficial in reducing vertical transmission due to ..
  16. Human Antibodies and Targeted Vaccines Against SARS-CoV
    Wayne A Marasco; Fiscal Year: 2008
    ..b>Passive immunization has proven to be an effective and safe strategy for the prevention and treatment of viral diseases...
  17. Human Monoclonal Antibodies for Bioterrorism Defense
    Ernest S Smith; Fiscal Year: 2005
    ..In order to develop an effective means of passive immunization against smallpox that can be protective for both infected individuals and their contacts, it will be ..
  18. Human Antibodies and Targeted Vaccines Against SARS-CoV
    Wayne A Marasco; Fiscal Year: 2007
    ..b>Passive immunization has proven to be an effective and safe strategy for the prevention and treatment of viral diseases...
  19. Human Monoclonal Antibodies against Botulinum Toxins
    Kim D Janda; Fiscal Year: 2007
    ..Human IgG will be the most suitable format for use in passive immunotherapy and/or prophylaxis against BoNTs and the condition of botulism...
  20. Mechanisms of Microglial Activation and Phagocytosis in*
    Gary E Landreth; Fiscal Year: 2005
    ..Schenk and colleagues have recently reported that either active or passive immunization of mice with anti-AB antibodies results in the prevention of amyloid deposition as well as the removal of ..
  21. Maternal Autoantibodies: Pathogenesis of Neonatal Lupus
    Jill P Buyon; Fiscal Year: 2007
    ..e., necessary maternal factor), accomplished by active and passive immunization. A unique transgenic model expressing human 52beta in the heart (increased antigen accessibility) will be ..
  22. Maternal Autoantibodies: Pathogenesis of Neonatal Lupus
    Jill P Buyon; Fiscal Year: 2006
    ..e., necessary maternal factor), accomplished by active and passive immunization. A unique transgenic model expressing human 52beta in the heart (increased antigen accessibility) will be ..
  23. Peptide Vaccines to Elicit HIV-1-Neutralizing Antibodies
    Jamie K Scott; Fiscal Year: 2006
    ..In this way, high-titer responses may be built from initially low ones. We have developed peptide leads for Mabs 2F5 and 2G12, and are doing so for the newly-discovered Mabs 4E10 and Z13; these will be similarly tested...
  24. Protective Human Monoclonal Antibodies to HIV1
    SUSAN B ZOLLA-PAZNER; Fiscal Year: 2007
    ..activity whose activity will complement those of previously described mAbs, which can be used for passive immunization, and whose epitopes can be characterized and incorporated into the design of candidate HIV vaccines, we ..
  25. Monoclonal Antibodies in Biodefense: Ebola Viruses
    Larry Zeitlin; Fiscal Year: 2008
    DESCRIPTION (provided by applicant): Passive immunization with antibodies has been shown to prevent a wide variety of viral, bacterial, fungal, and parasitic diseases that affect humans...
  26. Monoclonal Antibodies in Biodefense: Ebola Viruses
    Larry Zeitlin; Fiscal Year: 2007
    DESCRIPTION (provided by applicant): Passive immunization with antibodies has been shown to prevent a wide variety of viral, bacterial, fungal, and parasitic diseases that affect humans...
  27. Efficacy of DNA versus Protein Vaccine
    MYLIEN DAO; Fiscal Year: 2004
    ..to produce recombinant bacteria, protein and peptide vaccines for active immunization, and antibody for passive immunization. Various levels of protection were achieved with these vaccines...
  28. Therapeutic Approaches for Prion Disease
    Thomas M Wisniewski; Fiscal Year: 2008
    ..We propose that both active and passive immunization approaches will be effective at preventing prion infection...
  29. Statins for Alzheimer's disease immunotherapy
    Ken-Ichiro Fukuchi; Fiscal Year: 2008
    ..In addition, the clinical trials and passive immunization induced cerebral hemorrhages in one AD patient and some AD mouse models, respectively...
  30. Immunization to Block the Effects of Nicotine
    Paul R Pentel; Fiscal Year: 2007
    ..This study will examine two general approaches to enhancing the efficacy of immunization; (a) the use of passive immunization with monoclonal nicotine-specific antibodies to investigate the relationship of affinity and dose to ..
  31. Identification of Relaxin Receptor Antagonists
    SHEAU-YU T HSU; Fiscal Year: 2005
    ..b>Passive immunization with anti-relaxin antibodies during the anteparmm period reduces cervical growth and extensibility as well ..
  32. Monoclonal Antibodies for the Study of P. carinii
    Francis Gigliotti; Fiscal Year: 2008
    ..Our second goal is to define the effect of passive immunotherapy, with specific antibody, on the outcome of active Pcp with particular emphasis on the effect of antibody ..
  33. BIOCHEMISTRY AND FUNCTION OF NOVEL MONOKINES
    BARBARA A SHERRY; Fiscal Year: 2002
    ..With regard to sepsis, this will be addressed by passive immunization of mice with MIP-1a versus MIP-1b specific antibodies, and by direct administration of recombinant ..
  34. MONOCLONAL ANTIBODIES FOR ALZHEIMER'S IMMUNOTHERAPY
    ANDREW C HIATT; Fiscal Year: 2006
    ..These antibodies are candidates for use in passive immunotherapy. The potential advantages of a passive approach include: (1) the dose of drug given to any patient can be ..
  35. Molecular Aspects of Antitumor Antibodies
    Jeffrey V Ravetch; Fiscal Year: 2007
    DESCRIPTION (provided by applicant): Passive immunization with anti-tumor antibodies has resulted in clinical improvement in a variety of neoplastic diseases...
  36. Molecular Aspects of Antitumor Antibodies
    Jeffrey V Ravetch; Fiscal Year: 2008
    DESCRIPTION (provided by applicant): Passive immunization with anti-tumor antibodies has resulted in clinical improvement in a variety of neoplastic diseases...
  37. Live Attenuated Bacterial Vaccines Against Plaque
    James P Nataro; Fiscal Year: 2008
    DESCRIPTION (provided by applicant): Though novel therapeutic interventions and passive immunization will have vital, roles to play in biodefense, there is no substitute for pre-existing immunity to the major threats...
  38. IgG subclass and function of anti-polysaccharide abs
    John R Schreiber; Fiscal Year: 2005
    ..These studies will allow more rational strategies of active and passive immunization against bacteria, improved understanding of IgG subclass deficiency, and new information about which IgG ..
  39. Broad-Spectrum Therapeutic Human Antibodies for Dengue Virus Infections
    Yorgo Modis; Fiscal Year: 2006
    ..b>Passive immunization is an accepted medical practice to protect against infection...
  40. Strategies to Prevent SIV Binding to Macaque DC-SIGN
    Jason T Kimata; Fiscal Year: 2002
    ..antibodies to DC-SIGN as well as the SIV envelope that neutralize virus attachment to DC-SIGN and subsequent transfer to CD4+ T-cells will serve as a basis for vaccine and passive immunotherapy strategies aimed at preventing infection.
  41. Therapeutic delivery of single chain antibody for Alzheimer's disease
    Ken-Ichiro Fukuchi; Fiscal Year: 2008
    ..Although these passive immunization modalities may be effective in treating AD patients without inducing side effects such as inflammatory ..
  42. Therapeutic delivery of single chain antibody for Alzheimer's disease
    Ken-Ichiro Fukuchi; Fiscal Year: 2007
    ..Although these passive immunization modalities may be effective in treating AD patients without inducing side effects such as inflammatory ..
  43. Targeted antigen receptor treatment of cancer
    David A Scheinberg; Fiscal Year: 2008
    ..for therapy are explored active immunotherapy (vaccines) to generate antibody and T-cell responses and passive immunotherapy with antibodies (monoclonal antibodies, mAb). The Program has four projects that use new approaches (e.g...
  44. Producing Polyclonal Human Antibodies to Anthrax
    THILLAINAYAGAM SATHIYASSEELAN; Fiscal Year: 2005
    ..Despite high dose antibiotic therapy, several deaths occurred following the 2001 mail attack. Passive immunization with anti-anthrax immunoglobulins, in combination with antibiotics, is a promising approach for post-..
  45. Targeted antigen receptor treatment of cancer
    Alan N Houghton; Fiscal Year: 2007
    ..for therapy are explored active immunotherapy (vaccines) to generate antibody and T-cell responses and passive immunotherapy with antibodies (monoclonal antibodies, mAb). The Program has four projects that use new approaches (e.g...
  46. Targeted antigen receptor treatment of cancer
    DAVID A d-scheinberg@mskccorg PROFESSOR AND CHAIR SCHEINBERG; Fiscal Year: 2009
    ..for therapy are explored active immunotherapy (vaccines) to generate antibody and T-cell responses and passive immunotherapy with antibodies (monoclonal antibodies, mAb). The Program has four projects that use new approaches (e.g...
  47. Acquired Immunity and Vaccination for P. aeruginosa
    Gerald B Pier; Fiscal Year: 2008
    ..development of acquired immunity and the potential to develop effective reagents for active and passive immunization to augment the prevention and treatment off, aeruginosa infections. ..
  48. Recombinant antibodies as an anti-microbial shield
    Alexander Pereboev; Fiscal Year: 2004
    ..In many cases passive immunization with pre-formed antibodies can abrogate challenge by a pathologic microorganism...
  49. Diversification of Cytotoxic Effector Cells Via LPS-activated DCs
    ANNA KAROLINA karolinp@baylorhealthedu PROFESSOR PALUCKA; Fiscal Year: 2009
    ..While T cell immunity plays a role in the control of metastatic melanoma, passive immunotherapy is not expected to yield long-lasting immune memory...
  50. Primate Endometrial Responses to Placental MHC Class I Molecules
    Thaddeus G Golos; Fiscal Year: 2008
    ..We have recently demonstrated the biological relevance of primate placental MHC class I expression with passive immunization of rhesus monkeys during early pregnancy...
  51. Diversification of Cytotoxic Effector Cells Via LPS-activated DCs
    Anna Karolina Palucka; Fiscal Year: 2008
    ..While T cell immunity plays a role in the control of metastatic melanoma, passive immunotherapy is not expected to yield long-lasting immune memory...
  52. Immunization-induced AMI and CMI against malaria
    James M Burns; Fiscal Year: 2005
    ..Pc MSP-1 induced protective T cell and B cell responses defined in vitro will be validated in vivo by passive immunization studies and through the immunization of selected immunological knockout mice...
  53. AAV-mediated muscle-directed gene transfer for Alzheimer's disease
    Ken-Ichiro Fukuchi; Fiscal Year: 2008
    ..Although these passive immunization modalities may be effective in treating AD patients without inducing side effects such as inflammatory ..
  54. Peptide Vaccines from Neutralizing Antibodies 2F5 & 2G12
    Jamie K Scott; Fiscal Year: 2002
    ..b>Passive immunization with these MAbs produces sterilizing protection against IV and mucosal challenge of macaques with ..
  55. AAV-mediated muscle-directed gene transfer for Alzheimer's disease
    Ken-Ichiro Fukuchi; Fiscal Year: 2007
    ..Although these passive immunization modalities may be effective in treating AD patients without inducing side effects such as inflammatory ..
  56. SPORE in Skin Cancer
    Meenhard Herlyn; Fiscal Year: 2008
    ..and how therapeutic efficacy can be enhanced by cytokines, including IL-2 (Project 5); and c) active and passive immunotherapy of melanoma with lymphocytes and defined tumor antigens: an organotypic model of melanoma will define new ..
  57. Targeting GITR for Tumor Immunotherapy
    Adam D Cohen; Fiscal Year: 2008
    ..model that GITR ligation enhances immunity to melanoma self antigens, and can augment both active and passive immunotherapy against a poorly immunogenic tumor, with focal hypopigmentation as the only observable autoimmunity...
  58. PASSIVE IMMUNITY TO COCAINE USING NOVEL HUMAN ANTIBODIES
    Andrew B Norman; Fiscal Year: 2003
    ..These human antibodies should prove suitable for passive immunotherapy of cocaine dependent patients resulting in an effective treatment for cocaine addiction...
  59. Profile of beta-amyloid in response to beta-amyloid vacc
    Yasuji Matsuoka; Fiscal Year: 2002
    The accumulation of amyloid in transgenic mice has been reduced by vaccination with either Abeta peptide or passive immunization with anti-Abeta...
  60. Polyclonal human antibody in cloned HAC-transgenic cows
    Barbara A Osborne; Fiscal Year: 2006
    ..No mass vaccination program is envisioned for these toxins. In the absence of a vaccine, passive immunization with intravenous immunoglobulin (IVIG) of people exposed to bacterial enterotoxins has been suggested ..
  61. B. anthracis:passive immunization with anticapsular mAb
    Thomas R Kozel; Fiscal Year: 2006
    ..The proposed determination of protective efficacy is central to any effort at active or passive immunization that targets the B...
  62. Therapeutic Approaches for Prion Disease
    Thomas M Wisniewski; Fiscal Year: 2007
    ..We propose that both active and passive immunization approaches will be effective at preventing prion infection...

Publications62

  1. Effect of sleep deprivation on serum influenza-specific IgG
    K B Renegar
    Department of Physiology and Biophysics, University of Tennessee, Memphis, USA
    Sleep 21:19-24
    ..Thus, our data do not support the hypothesis that sleep-deprivation lowers existing serum antibody titers by accelerating antibody catabolism...
  2. Pneumococcal surface protein A is expressed in vivo, and antibodies to PspA are effective for therapy in a murine model of pneumococcal sepsis
    E Swiatlo
    Department of Medicine, University of Alabama at Birmingham, USA
    Infect Immun 71:7149-53
    ..Immunotherapy with antibodies to PspA may have some utility in treating pneumococcal infections in humans...
  3. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract
    Kathryn B Renegar
    Division of Infectious Diseases, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    J Immunol 173:1978-86
    ..b>Passive immunization with Ab doses resulting in serum IgG anti-influenza virus Ab titers far in excess of those observed in ..
  4. Protection of mice against Human respiratory syncytial virus by wild-type and aglycosyl mouse-human chimaeric IgG antibodies to subgroup-conserved epitopes on the G glycoprotein
    C Mekseepralard
    The Schools of Clinical Medical Sciences and Cell and Molecular Biosciences, The University of Newcastle upon Tyne, UK
    J Gen Virol 87:1267-73
    ..005). These results indicate that the protective effect of this antibody is mediated by both Fc-dependent and Fc-independent pathways...
  5. Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants
    Jianhua Sui
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, 44 Binney St, JFB 824, Boston, MA 02115, USA
    J Virol 79:5900-6
    ..Our study also cautions that for any prophylaxis strategy based on neutralizing antibody responses, whether by passive or active immunization, a genotyping monitor will be necessary for effective use...
  6. Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection
    Jean Mukherjee
    Tufts University School of Veterinary Medicine, North Grafton, Massachusetts 01536, USA
    Infect Immun 70:612-9
    ..The Stx2-neutralizing ability of these HuMAbs could potentially be used clinically to passively protect against HUS development in individuals infected with Stx-producing bacteria, including E. coli O157:H7...
  7. Protection of mice against experimental Japanese encephalitis virus infections by neutralizing anti-glycoprotein E monoclonal antibodies
    A K Gupta
    National Institute of Virology, Indian Council of Medical Research, 20 A, Dr Ambedkar Road, P O B No 11, Pune 411001, India
    Acta Virol 47:141-5
    ..Administration of combinations of two or more Hs MAbs may be recommended due to their possible enhanced protection against JE virus infections in mice...
  8. Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice
    Thomas C Greenough
    Department of Pediatrics, Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts 02130, USA
    J Infect Dis 191:507-14
    ..Antibodies to both epitopes protected mice against SARS-CoV challenge. Clinical trials are planned to test MAb 201, a fully human MAb specific for the epitope within the receptor-binding region...
  9. Cellular localization and antigenic characterization of crimean-congo hemorrhagic fever virus glycoproteins
    Andrea Bertolotti-Ciarlet
    Department of Microbiology, University of Pennsylvania, 225 Johnson Pavilion, 3610 Hamilton Walk, Philadelphia, PA 19104, USA
    J Virol 79:6152-61
    ..In addition, nonneutralizing antibody-dependent mechanisms, such as antibody-dependent cell-mediated cytotoxicity, may be involved in the in vivo protection seen with the MAbs to G(C)...
  10. Efficient mother-to-child transfer of antiretroviral immunity in the context of preclinical monoclonal antibody-based immunotherapy
    Laurent Gros
    Institut de Génétique Moléculaire de Montpellier, UMR 5535 IFR 122, CNRS, 1919 Route de Mende, 34293 Montpellier Cedex 5, France
    J Virol 80:10191-200
    ....
  11. The effect of monoclonal antibody and route of immunization on the humoral immune response against Porphyromonas gingivalis
    M L Van Tilburg
    Department of Oral Biology, University of Florida, Gainseville FL 32610, USA
    Oral Microbiol Immunol 16:153-62
    ..immune protection against pathogenic microorganisms and suggested to contribute to protection following passive immunization. To test whether a monoclonal antibody directed against an adhesion epitope of the periodontal pathogen ..
  12. Serum-derived IgG1-mediated immune exclusion as a mechanism of protection against H. pylori infection
    Jacqueline Keenan
    Department of Surgery, Christchurch School of Medicine, P O Box 4345, Christchurch, New Zealand
    Vaccine 20:2981-8
    ..In vitro immunogold electron microscopy supported this hypothesis, but also suggested that a threshold of H. pylori-specific antibody needs to be maintained if immune exclusion by the host is to overcome immune evasion by the bacteria...
  13. Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection
    D Martin
    Unité de Recherche en Vaccinologie, Centre de Recherche en Infectiologie, Centre Hospitalier Universitaire de Québec, Ste Foy, Canada
    J Exp Med 185:1173-83
    ..The fact that the NspA protein can elicit the production of bactericidal and protective antibodies emphasize its potential as a vaccine candidate...
  14. Protection mediated by antibodies to iron-regulated outer-membrane proteins of S. typhi in a mouse peritonitis model
    Shaloo Sood
    Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
    Mol Cell Biochem 273:69-78
    ..This study, thus indicates that anti IROMPs antibodies may play an important role in providing protection at systemic as well as at mucosal level...
  15. Peptide mimics of the group B meningococcal capsule induce bactericidal and protective antibodies after immunization
    Carla Lo Passo
    Dipartimento di Scienze Microbiologiche, Genetiche e Molecolari, Università degli Studi di Messina, Messina, Italy
    J Immunol 178:4417-23
    ..Moreover, the occurrence of bacteremia was prevented in infant rats by administration of immune sera before MenB challenge. 9M is a promising lead candidate for the development of an effective and affordable anti-MenB vaccine...
  16. In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity
    Herman F Staats
    Department of Pathology, Box 3712, DUMC, Durham, NC 27710, USA
    Infect Immun 75:5443-52
    ..Thus, this LeTx neutralization assay may be a more biologically relevant neutralization assay to predict the in vivo protective capacity of LeTx-neutralizing antibodies...
  17. Production and characterization of protective human antibodies against Shiga toxin 1
    Jean Mukherjee
    Division of Infectious Diseases, Tufts University School of Veterinary Medicine, North Grafton, Massachusetts, USA
    Infect Immun 70:5896-9
    ..Medarex) animals, human monoclonal antibodies (Hu-MAbs) were developed against Shiga toxin 1 (Stx1) for passive immunotherapy of HUS...
  18. Protective efficacy of IgA monoclonal antibodies to O and H antigens in a mouse model of intranasal challenge with Salmonella enterica serotype Enteritidis
    Ianko D Iankov
    Department of Microbiology, Medical University of Sofia, Zdrave 2 Street, 1431 Sofia, Bulgaria
    Microbes Infect 6:901-10
    ..n. with a high dose of virulent S. enteritidis strain. Thus, secretory IgA (S-IgA) directed against O:9 antigen alone can prevent bacterial invasion in the respiratory epithelium...
  19. Development and application of an oral challenge mouse model for studying Clostridium perfringens type D infection
    Mariano E Fernandez Miyakawa
    California Animal Health and Food Safety Laboratory System, San Bernardino Branch, University of California Davis, 105 West Central Avenue, San Bernardino, CA 92408, USA
    Infect Immun 75:4282-8
    ..However, mice could be protected against lethality by intravenous passive immunization with an epsilon toxin antibody prior to oral challenge...
  20. Mouse models of IgG- and IgM-mediated hemolysis
    David A Schirmer
    Department of Pathology, Columbia University, New York, NY 10023, USA
    Blood 109:3099-107
    ..quot; Passive immunization of non-Tg mice with the IgG1 10F7 and IgG3 NaM10-2H12 anti-hGPA mAbs each induced rapid clearance of ..
  21. Immunogenicity of meningococcal PBP2 during natural infection and protective activity of anti-PBP2 antibodies against meningococcal bacteraemia in mice
    Maria Leticia Zarantonelli
    Neisseria Unit, National Reference Center for Meningococci, Department of Molecular Medicine, Institut Pasteur, 25 28 Rue du Dr Roux, 75724 Paris Cedex 15, France
    J Antimicrob Chemother 57:924-30
    ..CONCLUSION: These data argue for considering meningococcal PBP2 as a vaccine candidate...
  22. Blocking immune evasion as a novel approach for prevention and treatment of herpes simplex virus infection
    Kara A Judson
    Infectious Disease Division, Department of Medicine, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104-6073, USA
    J Virol 77:12639-45
    ..These results suggest that it is possible to block immune evasion domains on herpes simplex virus and that this approach has therapeutic potential and may enhance vaccine efficacy...
  23. Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication
    M Gupta
    Special Pathogens Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    J Virol 75:4649-54
    ..Thus antibodies suppress or delay viral growth, provide protection against lethal Ebola virus infection, and may not require participation of other immune components for protection...
  24. Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge
    Shlomo Lustig
    Laboratory of Viral Diseases, National Institutes of Health, 4 Memorial Dr, MSC 0445, Bethesda, MD 20892-0445, USA
    J Virol 79:13454-62
    ..These studies suggest that antibodies to two or three viral membrane proteins optimally derived from the outer membranes of IMV and EV, may be beneficial for prophylaxis or therapy of orthopoxvirus infections...
  25. Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge
    Barry Rockx
    Department of Epidemiology, 2107 McGavran Greenberg, CB 7435, University of North Carolina, Chapel Hill, NC 27699 7435, USA
    J Virol 82:3220-35
    ....
  26. Passive immunization with neutralizing antibodies interrupts the mouse mammary tumor virus life cycle
    M Mpandi
    Swiss Institute for Experimental Cancer Research. Institute of Biochemistry, University of Lausanne, Switzerland
    J Virol 77:9369-77
    ..In conclusion, systemic neutralizing monoclonal antibodies can provide an efficient protection against chronic retroviral amplification and persistence...
  27. Venezuelan equine encephalitis virus complex-specific monoclonal antibody provides broad protection, in murine models, against airborne challenge with viruses from serogroups I, II and III
    R J Phillpotts
    Biomedical Sciences, Dstl, Porton Down, Salisbury SP4 0JQ, UK
    Virus Res 120:107-12
    ..1985. J. Virol. 55, 594-600]. Development of an analogous human MAB with identical VEEV epitope specificity may be informed and monitored by reference to these properties...
  28. Epitope determinants of a chimpanzee dengue virus type 4 (DENV-4)-neutralizing antibody and protection against DENV-4 challenge in mice and rhesus monkeys by passively transferred humanized antibody
    CHING JUH LAI
    Laboratory of Infectious Diseases, National Institutes of Health, 50 South Drive MSC 8005, Bethesda, MD 20892, USA
    J Virol 81:12766-74
    ..This substitution was also present in all naturally occurring isolates belonging to DENV-4 genotype III. These studies have important implications for possible antibody-mediated prevention of DENV infection...
  29. In vitro efficiency of intra- and extracellular immunization with mouse anti-YGNNV antibody against yellow grouper nervous necrosis virus
    Yu Shen Lai
    Molecular Genetics Laboratory, Institute of Zoology, Academia Sinica, 128 Academia Road, Section 2, Nankang, Taipei 11529, Taiwan
    Vaccine 20:3221-9
    ....
  30. A humanized murine monoclonal antibody protects mice either before or after challenge with virulent Venezuelan equine encephalomyelitis virus
    Ann R Hunt
    Arbovirus Diseases Branch, Division of Vector-Borne Infectious Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Public Health Service, US Department of Health and Human Services, Fort Collins, CO 80522, USA
    J Gen Virol 87:2467-76
    ..Importantly, therapeutic administration of the humanized mAb to mice already infected with VEEV cured 90 % of mice treated with Hy4 IgG within 1 h of VEEV inoculation and 75 % of mice treated 24 h after virus infection...
  31. Protective efficacy of neutralizing antibodies against Ebola virus infection
    Ayato Takada
    Department of Global Epidemiology, Hokkaido University Research Center for Zoonosis Control, Sapporo 060 0818, Japan
    Vaccine 25:993-9
    ..These results underscore the potential therapeutic utility of monoclonal antibodies for postexposure treatment of Ebola virus infections...
  32. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza
    Cameron P Simmons
    Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh City, Viet Nam
    PLoS Med 4:e178
    ..A panel of neutralizing, cross-reactive mAbs might be useful for prophylaxis or adjunctive treatment of human cases of H5N1 influenza...
  33. Gamma 3 gene-disrupted mice selectively deficient in the dominant IgG subclass made to bacterial polysaccharides. II. Increased susceptibility to fatal pneumococcal sepsis due to absence of anti-polysaccharide IgG3 is corrected by induction of anti-polysa
    John McLay
    Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA
    J Immunol 168:3437-43
    ..pneumoniae glycoconjugate can adequately protect against S. pneumoniae sepsis. This model suggests that IgG subclass of anti-PS Ab is an important component of immunity to encapsulated bacteria...
  34. A coordinated cytotoxic effect of IFN-gamma and cross-reactive antibodies in the pathogenesis of Helicobacter pylori gastritis
    Toshiyuki Itoh
    Department of Clinical Bio-regulatory Science, Kyoto University Graduate School of Medicine, 54 Kawahara-cho Shogoin, Sakyo-ku, Kyoto City 606-8507, Japan
    Helicobacter 8:268-78
    ..pylori antibodies to complement-binding subclass and by augmenting cytotoxic activity of a certain autoantibody. This may explain a host-dependent diversity in gastric pathology of the patients with H. pylori infection...
  35. Concomitant administration of Yersinia pestis specific monoclonal antibodies with plague vaccine has a detrimental effect on vaccine mediated immunity
    Jim E Eyles
    Biomedical Sciences Department, Dstl, Porton Down, Wiltshire SP4 0JQ, UK
    Vaccine 25:7301-6
    ..pestis: intradermal injection might therefore be considered as a potential minimally invasive method of plague vaccine administration. These data have implications for the design of therapeutic strategies against plague infection...
  36. Functional characteristics of a protective monoclonal antibody against serotype A and C lipooligosaccharides from Moraxella catarrhalis
    W G Hu
    Laboratory of Immunology, National Institute on Deafness and Other Communication Disorders, Rockville, Maryland 20850, USA
    Infect Immun 69:1358-63
    ..MAb 8E7 inhibited the adherence of strain O35E to Chang conjunctival epithelial cells by 90%. Passive immunization with MAb 8E7 could significantly enhance the clearance of strain O35E from mouse lungs in an aerosol ..
  37. Klebsiella pneumoniae type 3 fimbria-mediated immunity to infection in the murine model of respiratory disease
    Heather Lavender
    College of Medicine, Department of Microbiology, University of Iowa, Iowa City, IA 52242, USA
    Int J Med Microbiol 295:153-9
    ..However, challenge with a high number of bacteria resulted in no protection against infection...
  38. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations
    Heidi H Van Ojik
    Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, 3000 DR Rotterdam, The Netherlands
    Cancer Res 63:5595-600
    ..In contrast, other effector cell populations, including granulocytes, contribute to the antitumor activity of CpG B and mAbs. FcgammaRI plays an important role in this activity...
  39. Characterization of gp70 and anti-gp70 monoclonal antibodies in Paracoccidioides brasiliensis pathogenesis
    Daniela de Mattos Grosso
    Departamento de Microbiologia, Imunologia e Parasitologia, Universidade Federal de São Paulo, UNIFESP, Brazil
    Infect Immun 71:6534-42
    ..To corroborate this hypothesis, we analyzed the effect of passive immunization of mice during infection with P. brasiliensis using anti-gp70 MAbs...
  40. Passive protection studies in mice with monoclonal antibodies directed against the non-structural protein NS3 of dengue 1 virus
    C H Tan
    Department of Microbiology, Faculty of Medicine, National University of Singapore, Kent Ridge
    J Gen Virol 71:745-9
    ..Monoclonal antibodies to NS3 of dengue 1 virus are able to increase the survival time of mice challenged with a lethal dose of dengue 1 virus, although the mechanism remains to be defined...
  41. Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax
    Mark T Albrecht
    Biological Defense Research Directorate, Naval Medical Research Center, 12300 Washington Ave, Silver Spring, MD 20910 7500, USA
    Infect Immun 75:5425-33
    ..One approach is passive immunization through the administration of antibodies that mitigate the biological action of anthrax toxin...
  42. Vaccination with nontoxic mutant toxic shock syndrome toxin 1 protects against Staphylococcus aureus infection
    Dong-Liang Hu
    Department of Bacteriology, Hirosaki University School of Medicine, Hirosaki, Japan
    J Infect Dis 188:743-52
    ..aureus infection and that the protection might be mediated by TSST-1-neutralizing antibodies as well as by the down-regulation of IFN-gamma production...
  43. Streptococcus pneumoniae pilus subunits protect mice against lethal challenge
    Claudia Gianfaldoni
    Novartis Vaccines and Diagnostics s r l, Research Center, Via Fiorentina 1, I 53100 Siena, Italy
    Infect Immun 75:1059-62
    ..Both active and passive immunization with recombinant pilus subunits afforded protection against lethal challenge with the S...
  44. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus
    C N Wu
    Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan, ROC
    Vaccine 20:895-904
    ..Our data indicated that inactivated virus is the choice of vaccine preparation capable of fulfilling the demand for effective control, and that VP1 subunit vaccines remain promising vaccine strategies that require further refinement...
  45. Determining liver stage parasite burden by real time quantitative PCR as a method for evaluating pre-erythrocytic malaria vaccine efficacy
    A A Witney
    Malaria Program, Naval Medical Research Center, 503 Robert Grant Avenue, Room 3A4O, Silver Spring, MD 20910-7500, USA
    Mol Biochem Parasitol 118:233-45
    ..Our data establish this quantitative real-time PCR assay to be a fast and reproducible way of accurately assessing liver stage parasite burden and vaccine efficacy in rodent malaria models...
  46. Role of systemic and mucosal immune responses in reciprocal protection against Bordetella pertussis and Bordetella parapertussis in a murine model of respiratory infection
    Mineo Watanabe
    Department of Microbiology and Biologicals, Daiichi College of Pharmaceutical Sciences, Fukuoka 815 8511, Japan
    Infect Immun 71:733-8
    ..b>Passive immunization with serum from mice infected with B. pertussis established protective immunity against B...
  47. The genetic background of Streptococcus pneumoniae affects protection in mice immunized with PspA
    Xiangyun He
    Department of Microbiology, The University of Mississippi Medical Center, Jackson, MS 39216, USA
    FEMS Microbiol Lett 269:189-95
    ..We localized the protection-eliciting region to the first 122 amino acid residues of the N-terminus of the alpha-helical domain of PspA/EF5668...
  48. Evaluation of an in vitro assay aimed at measuring protective antibodies against sporozoites
    S Mellouk
    Malaria Program, Naval Medical Research Institute, Bethesda, MD 20889 5055
    Bull World Health Organ 68:52-9
    ..These data show a close correlation between in vivo and in vitro findings and thus suggest that the inhibition of liver-stage development assay (ILSDA) appears appropriate to evaluate the potential of antibodies...
  49. Stimulation of antiviral antibody response in SHIV-IIIB-infected macaques
    S Muller
    Immpheron, Inc, Lexington, KY 40503, USA
    Scand J Immunol 54:383-95
    ..These data show that the MoAb 1F7 injections of chronically SHIV-IIIB-infected macaques resulted in idiotype-specific clonal suppression with broadening the antibody response to HIV envelope proteins...
  50. Use of neutralizing murine monoclonal antibodies to rabies glycoprotein in passive immunotherapy against rabies
    Kader Muhamuda
    Department of Neurovirology, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka, India
    Hum Vaccin 3:192-5
    b>Passive immunization is an important parameter of post exposure rabies prophylaxis. Two types of rabies immunoglobulin (RIGs) are currently available for Passive immunization against rabies i.e...
  51. Specific antibodies contribute to the host protection against strains of Francisella tularensis subspecies holarctica
    Stephan Stenmark
    Department of Clinical Microbiology, Infectious Diseases, Umeå University, Ume, Sweden
    Microb Pathog 35:73-80
    ..Together, these findings show that specific antibodies contribute to the host defence of mice against F. tularensis subsp. holarctica...
  52. Susceptibility of the different developmental stages of the asexual (schizogonic) erythrocyte cycle of Plasmodium chabaudi chabaudi to hyperimmune serum, immunoglobulin (Ig)G1, IgG2a and F(ab')2 fragments
    R A Cavinato
    Department of Parasitology, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, SP, Brazil
    Parasite Immunol 23:587-97
    ..However, FcgammaR-mediated interactions, or other mechanisms not yet defined, may also contribute to inhibit erythrocyte reinvasion...
  53. Immune system pathogenesis is prevented by the neutralization of the systemic trans-sialidase from Trypanosoma cruzi during severe infections
    M G Risso
    Departamento de Microbiología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina
    Parasitology 134:503-10
    ....
  54. The in vitro and in vivo protective activity of monoclonal antibodies directed against Hantaan virus: potential application for immunotherapy and passive immunization
    Zhikai Xu
    Department of Microbiology, the Fourth Medical University of PLA, Xi an, 710032, People s Republic of China
    Biochem Biophys Res Commun 298:552-8
    ..Phase II clinical trials of these neutralizing MAbs for emergent treatment of patients with HTNV infection in early stages of HRFS are carried out in endemic areas in China...
  55. Successful treatment of rotavirus-induced diarrhoea in suckling mice with egg yolk immunoglobulin
    Shafiqul A Sarker
    ICDDR, GPO Box 128, Dhaka 1000, Bangladesh
    J Health Popul Nutr 25:465-8
    ..Oral immunoglobulin therapy with egg yolk-derived anti-rotavirus immunoglobulins has previously been shown to achieve moderate ..
  56. Immune response to postprimary tuberculosis in mice: Mycobacterium tuberculosis and Miycobacterium bovis bacille Calmette-Guérin induce equal protection
    Hans Joachim Mollenkopf
    Department of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany
    J Infect Dis 190:588-97
    ....
  57. Passive protection against Burkholderia pseudomallei infection in mice by monoclonal antibodies against capsular polysaccharide, lipopolysaccharide or proteins
    S M Jones
    Microbiology, Dstl, CBS Porton Down, Salisbury, Wiltshire SP4 0JQ, UK
    J Med Microbiol 51:1055-62
    ..However, at a higher B. pseudomallei challenge level of 10(6) cfu none of the MAbs afforded protection and only the anti-exopolysaccharide MAbs produced a significantly delayed time to death...
  58. Immunotherapy of hepatoma with a monoclonal antibody against murine endoglin
    Guang hong Tan
    Hainan Provincial Key Laboratory of Tropical Medicine, Hainan Medical College, Haikou 571101, Hainan Province, China
    World J Gastroenterol 13:2479-83
    ..In addition, tumor cell apoptosis was detected by TUNEL assay. RESULTS: Passive immunotherapy with anti-endoglin mAb could effectively suppress tumor growth, and prolonged the survival time of ..